Abstract: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.

Abstract: The innovative treatment strategy described here utilizes configurable microscopic medical payload delivery devices to act as a transport vector to deliver quantum genes to specific type of cells in the body. Utilizing probes on the exterior of the transport device, transport device locate specific target cell types in the body. Once a specific target cell type has been encountered, the configurable microscopic medical payload delivery device inserts its payload of quantum genes into the target cell type. By delivering quantum genes to specific type of cells, genes can be activated or inactivated in those specific type of cells. These medically therapeutic quantum genes are intended to improve cell function or the longevity of cells or neutralize harmful cells that pose a hazard to the general health of the body.

Abstract: The innovative treatment method described here utilizes configurable microscopic medical payload delivery devices to act as a transport vector to deliver quantum genes to specific type of cells in the body. Utilizing probes on the exterior of the transport device, transport device locate specific target cell types in the body. Once a specific target cell type has been encountered, the configurable microscopic medical payload delivery device inserts its payload of quantum genes into the target cell type. By delivering quantum genes to specific type of cells, genes can be activated or inactivated in those specific type of cells. This method of delivering medically therapeutic quantum genes to specific cells is intended to improve cell function or extend the longevity of cells or neutralize harmful cells that pose a hazard to the body.

Abstract: Amphoteric liposomes are proposed, which comprise positive and negative membrane-based or membrane-forming charge carriers as well as the use of these liposomes.

Abstract: A composition for the treatment of bruising is disclosed. The composition can include an antioxidant, one or more citrus flavanoids, as active agents along with a pharmaceutically acceptable excipient or filler. The compositions are nutriceutical formulations having the capacity to reduce the number of bruises that occur over time and that reduce the healing time of bruises. The compositions are preferably in tablet form for oral consumption one or more times per day. A method of reducing bruising is also disclosed in which a patient in need of a treatment for bruising or at risk of developing bruises is identified. The composition can then be administered orally to the patient.

Abstract: The present invention encompasses vaccine and/or immunogenic compositions against HIV and their methods of use for the prevention and/or treatment of HIV infection and/or AIDS. The vaccine and/or immunogenic compositions may contain an isolated HIV protein or fragment thereof, an adjuvant comprising a Toll like receptor (TLR) 4 ligand, in combination with a saponin.

Abstract: This invention describes a genetic system for targeting the EVI1 gene in mammalian cells. The EVI1 gene is an oncogenic transcription factor that, when expressed, accelerates cell division and inhibits death of cells. Nucleotide sequences that block the expression of EVI1 and drug delivery systems for them are described. These nucleotide sequences cause a block in cell growth and division and trigger death of mammalian cells, including lung and ovarian cancer cells.

Abstract: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.

Abstract: Disclosed are synthetic nanocarrier compositions with separate adjuvant compositions as well as related methods.

Abstract: The invention relates, at least in part, to compositions comprising populations of synthetic nanocarriers that comprise different sets of antigens as well as related methods.

Abstract: Inflammatory diseases in the CNS can be treated or alleviated by the administration of an oligonucleotide in an amount sufficient to reduce the influx of mononuclear cells to the central nervous system by down-regulating the expression of at least one cell surface marker. For example multiple sclerosis can be treated or at least alleviated, by the administration of an oligonucleotide in a dose effective to inhibit or reduce the influx of mononuclear and/or autoaggressive cells to the central nervous system. The oligonucleotide can be used alone, or in combination with other treatment strategies.

Abstract: Aminoalcohol lipidoids are prepared by reacting an amine with an epoxide-terminated compound are described. Methods of preparing aminoalcohol lipidoids from commercially available starting materials are also provided. Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these aminoalcohol lipidoid compounds, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive lipidoids and polynucleotide have been prepared. The inventive lipidoids may also be used in preparing microparticles for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.

Abstract: The present invention relates to a technology and method of priming of an immune response using invariant chain linked antigen, when these are used to prime a subsequent booster immunization using any suitable vacci.

Abstract: The invention provides compositions and methods for delivering agents to localized regions, tissues, or organs in vivo by conjugating agent-loaded nanoparticles to cells having homing capability. The agents may be therapeutic or diagnostic agents such as cancer chemotherapeutic agents and imaging agents respectively.

Abstract: Nano-constructscomprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.

Abstract: Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.

Abstract: The invention relates to a nucleic acid preparation with a content of below 1% protein, preferably below 0.1% protein, free of ethidium bromide, phenol, cesium chloride and detergents based on octyl phenol poly(ethylene glycol ether)n and with a content of below 1 EU/mg DNA of endotoxins. Said preparation is suitable as a drug particularly in gene therapy.

Abstract: Disclosed are peptides which inhibit the enzymatic activity of tyrosinase as well as formulations and methods for their use in the reduction of skin pigmentation, and methods of administering the inhibitory peptides in a topical formulation. Methods of skin treatment are also provided, the methods further including use of a peptide characterized by the amino acid sequence SFLLRN (SEQ ID NO: 1).

Abstract: A specific method is provided of improving immunomodulatory properties of Lactobacillus strains using growth media with a specific primary carbon source, including a method of increasing the anti-inflammatory effect of non-pathogenic anti-inflammatory bacterial strains, by the use of specific growth conditions.

Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.

Abstract: The present invention provides for the coaxial encapsulation of a plurality of cells in a single elongated compartment. By this encapsulation, the cells are protected by at least one layer of separation material and kept in close contact, which leads to a better vitality of the encapsulated cells and consequently results in higher chances to form microtissue. Methods and devices for the production of such encapsulated cell compartments are disclosed as well as medical uses of such compartments in cell, tissue therapy and tissue engineering.

Abstract: Aspects of the present application relate to pharmaceutical formulations comprising a nonsteroidal anti-inflammatory drug, together with a proton pump inhibitor drug, to reduce the incidence of gastrointestinal complications associated with chronic therapy with a nonsteroidal anti-inflammatory drug. Specific aspects of the application relate to fixed dose combinations comprising aspirin, or a derivative thereof, and omeprazole or esomeprazole, or pharmaceutically acceptable salts, solvates, or hydrates thereof.

Abstract: The invention is related to a water-free liquid or semisolid pharmaceutical composition comprising a derivatized insulin peptide, at least one polar organic solvent and at least one lipophilic component and a method of treatment using such.

Abstract: The present invention relates to a multiparticulate tablet with improved gastro-protection comprising at least a pharmaceutically active substance in the form of enteric coated particles, and a mixture of tableting excipients, wherein the said mixture of excipients comprising xylitol and/or maltitol, each in a directly compressible form, a disintegrating agent, a lubricant and at least one other diluent and the ratio of a) the xylitol and/or the maltitol to b) the other diluent(s) is less than 5/95 (weight/weight) and the result of the “test of integrity of the film” is greater than 95%, preferably greater than 97% and more preferably still greater than 99% and the result of the “release test” is greater than 90%, preferably greater than 95%. According to one embodiment of the invention, the active substance is omeprazole or esomeprazole. According to another embodiment the tablet is a disintegratable tablet, which disintegrate in the mouth with or without chewing.

Abstract: The invention consists of a new formulation of ibuprofen and codeine in the form of a tablet, which comprises L-leucine in a concentration ranging between 4%-15% as a lubricant, in order to prevent the formulation mixture from adhering to the punches and to other elements of the compression machine during the compression process. The new formulation additionally comprises talc (0.5%-5.0%) and silicified microcrystalline cellulose (30%-80%). The formulation is preferably arranged in the form of a core that comprises the active principles and, amongst others, the L-leucine, part of the talc and the silicified microcrystalline cellulose; this core is coated with a composition that contains a copolymer of methacrylic acid and ethyl acrylate.

Abstract: The invention relates to a process for the preparation of tablets containing moxifloxacin, comprising the steps of (i) providing moxifloxacin, pharmaceutically acceptable salts, solvates or hydrates thereof, optionally mixed with one or more pharmaceutical excipients; (ii) compacting it into a slug; (iii) granulating the slug; and (iv) compressing the resulting granules into tablets; and also tablets, granules and compacted material containing compacted moxifloxacin.

Abstract: Compositions of predetermined amounts of R(+) pramipexole and S(?) pramipexole and methods of using the same, including for the treatment and prevention of Parkinson's disease, are provided.

Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.

Abstract: The present invention relates to drug delivery compositions in the form of thin water-soluble films (wafers), which contain small particles that comprise at least one progestin and at least one protective agent. The protective agent provides effective taste-masking of the progestin due to limited release of the progestin in the mouth. The progestin is hence not absorbed via the buccal route, but rather via the enteral (per-oral) route.

Abstract: This invention relates to matrix patches for the topical (i.e., transdermal) delivery of piroxicam and methods for the treatment of acute and chronic pain and inflammation therewith, particularly pain and inflammation caused by sports injuries or other muscle aches or injuries requiring the application of analgesic and/or anti-inflammation medication, in this instance, piroxicam.

Abstract: A macroporous hydrogel sponge is provided selected from: (i) a synthetic polymer hydrogel sponge, and (ii) a synthetic polymer-polypeptide conjugate hydrogel sponge, the macroporous hydrogel sponge being at least 20% porous and having a pore diameter of 50-1000 ?m, wherein said synthetic polymer is crosslinked to an extent determined by effecting the crosslinkig of the synthetic polymer or synthetic polymer-polypeptide conjugate in the presence of at least about 30% by weight crosslinking agent.

Abstract: Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient.

Abstract: Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

Abstract: Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic. Also disclosed are particles and compositions that include disclosec chimeric therapeutics.

Abstract: Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic. Also disclosed are particles and compositions that include disclosed chimeric therapeutics.

Abstract: Chimeric therapeutics are disclosed that include a modified viral core protein and a nucleic acid bound to the modified viral core protein. The nucleic acid may be substantially homologous to a specific gene target. In some embodiments, the nucleic acid bound to the modified viral core protein is substantially non-immunogenic. Also disclosed are particles and compositions that include disclosec chimeric therapeutics.

Abstract: Provided are a photosensitizer-metal nanoparticle complex and a composition for photodynamic therapy or diagnosis having the same. The complex includes a photosensitizer, a metal nanoparticle, and a backbone linking the photosensitizer with the metal nanoparticle. The backbone has a polypeptide substrate capable of being specifically degraded by a protease. When the complex is administered to a patient, fluorescence and production of reactive oxygen species from the conjugated photosensitizers are inhibited in normal tissues due to the resonance energy transfer between the photosensitizer and metal nanoparticles, but in tumor tissues, fluorescence and production of reactive oxygen species from the released photosensitizers are activated, thereby effectively destroying the tumor tissues. In addition, the selective fluorescence in the tumor tissues can further improve accuracy of tumor diagnosis using the protease-activatable photosensitizer-metal nanoparticle complex.

Abstract: The present invention relates to a granule of gamma-hydroxybutyric acid or of one of its pharmaceutically acceptable salts, characterized in that it comprises a solid core on which the gamma-hydroxybutyric acid or one of its salts is supported.

Abstract: A drug targeting system for administering a pharmacologically active substance to the central nervous system of a mammal across the animal's blood brain barrier. The drug targeting system comprises nanoparticles made of poly(DL-lactide) and/or poly(DL-lactide-co-glycolide), a pharmacologically active substance which is absorbed to, adsorbed to, and/or incorporated into the nanoparticles, and either contains TPGS or comprises a pluronic 188 surfactant coating deposited on the drug-loaded nanoparticles.

Abstract: A process is described for loading hydrophilic polymer particles with a water-insoluble solvent-soluble drug. The particles are preferably embolic agents. The method provides particles having little or no drug at the surface and in a surface layer, whereby the burst effect is minimised. The drug is precipitated in the core of the particle, leading to extended release. The drug is, for instance, paclitaxel, rapamycin, dexamethasone or ibuprofen.

Abstract: The present invention provides novel nanoscale cellulose particles and also a process for their production. The cellulose-based particles obtained have volume -averaged particle sizes of less than 300 nm. These nanoparticles are produced from amorphous cellulose or by amorphization of cellulose, optional subsequent hydrolysis and by input of energy into a water-containing medium after or during dispersion.

Abstract: A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided.

Abstract: A Salvia hispanica L. derived seed oil extract composition of matter containing from 60-88% PUFAS in a ratio of from 3.1:1-3.3:1 of ALA to LA, 4-10% of C-18 mono-unsaturated fatty acid, 1-5% of C-18 saturated fatty acid and 4-8% of C-16 saturated fatty acid in a mixed triglyceride form stable at room temperature of 12-24 months containing a mixture of selected antioxidants.

Abstract: A composition of pesticide is a composed of banana oil, pepper powder, urea, and milk powder. Banana oil is composed of ethyl acetate, n-butyl acetate, n-butanol, ketone, benzol, and xylene. Banana oil is diluted with water at a proper ratio. Pepper powder is added to banana oil to provide an excellent effect of pest killing. Urea is diluted with water at a proper ratio. Milk powder is added to urea to provide protection to plant leaves. With such a composition, a practical improvement of being environmentally conservative, toxicant free, and pollution free is realized.

Abstract: The invention provides a mineral complex comprising about 40 wt. % to about 60 wt. % SiO2, about 6 wt. % to about 16 wt. % Fe2O3, about 4 wt. % to about 12 wt. %. CaO, and about 2 wt. % to about 8 wt. % MgO. The invention also provides animal feeds comprising the mineral complex. Methods for increasing the feed efficiency and weight gain in an animal by administering the mineral complex or an animal feed comprising the mineral complex also are provided.

Abstract: The invention provides a mineral complex comprising about 40 wt. % to about 60 wt. % SiO2, about 6 wt. % to about 16 wt. % Fe2O3, about 4 wt. % to about 12 wt. %. CaO, and about 2 wt. % to about 8 wt. % MgO. The invention also provides animal feeds comprising the mineral complex. Methods for increasing the feed efficiency and weight gain in an animal by administering the mineral complex or an animal feed comprising the mineral complex also are provided.

Abstract: The invention provides a mineral complex comprising about 40 wt. % to about 60 wt. % SiO2, about 6 wt. % to about 16 wt. % Fe2O3, about 4 wt. % to about 12 wt. %. CaO, and about 2 wt. % to about 8 wt. % MgO. The invention also provides animal feeds comprising the mineral complex. Methods for increasing the feed efficiency and weight gain in an animal by administering the mineral complex or an animal feed comprising the mineral complex also are provided.

Abstract: The invention provides a mineral complex comprising about 40 wt. % to about 60 wt. % SiO2, about 6 wt. % to about 16 wt. % Fe2O3, about 4 wt. % to about 12 wt. %. CaO, and about 2 wt. % to about 8 wt. % MgO. The invention also provides animal feeds comprising the mineral complex. Methods for increasing the feed efficiency and weight gain in an animal by administering the mineral complex or an animal feed comprising the mineral complex also are provided.

Abstract: A treatment system and method for osteopenia and osteoporosis using non-synthetic bio-available hormones, vitamins, minerals, and agents may be customized by varying the dosage and formulation of the components to maximize therapeutic effect, bioavailability, and patient comfort and compliance with their treatment method, the treatment system including a storage unit including a determined number of applications of hormones, minerals, and vitamins of appropriate dosages for treating the patient with osteopenia and osteoporosis.

Abstract: The invention provides a liquid composition containing (a) an acidic oxidant, (b) nitric acid or a salt thereof, and (c) at least one carboxylic acid selected from the group consisting of monocarboxylic acids, dicarboxylic acids, and tricarboxylic acids, or a salt thereof. The liquid composition can be used to disinfect or sterilize a subject that includes a portion made of an aluminum-based metal.